Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the company’s stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $21.33, for a total transaction of $69,322.50. Following the completion of the sale, the chief financial officer now owns 23,000 shares of the company’s stock, valued at approximately $490,590. This trade represents a 12.38 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Benjamin Hohl also recently made the following trade(s):

• On Monday, March 24th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.50, for a total transaction of $22,500.00.
• On Thursday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.41, for a total value of $66,332.50.
• On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.52, for a total value of $22,520.00.
• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.59, for a total transaction of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00.

Enliven Therapeutics Trading Down 6.6 %

Enliven Therapeutics stock opened at $19.68 on Tuesday. Enliven Therapeutics, Inc. has a 1-year low of $15.96 and a 1-year high of $30.03. The firm’s fifty day simple moving average is $21.24 and its 200-day simple moving average is $23.72. The company has a market capitalization of $964.40 million, a P/E ratio of -10.36 and a beta of 1.04.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.07. The company had revenue of $0.03 million for the quarter. On average, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its holdings in Enliven Therapeutics by 3.5% during the fourth quarter. Invesco Ltd. now owns 15,072 shares of the company’s stock valued at $339,000 after purchasing an additional 508 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Enliven Therapeutics by 3.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company’s stock worth $451,000 after buying an additional 718 shares during the period. Tower Research Capital LLC TRC grew its stake in Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after buying an additional 1,114 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Enliven Therapeutics by 14.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock worth $233,000 after acquiring an additional 1,275 shares during the period. Finally, MetLife Investment Management LLC lifted its position in Enliven Therapeutics by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 21,746 shares of the company’s stock worth $489,000 after acquiring an additional 1,285 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. BTIG Research began coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 price target on the stock. HC Wainwright upped their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $38.75.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.